Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness of drug monitoring of anti-TNF therapy in inflammatory bowel disease and rheumatoid arthritis: a systematic review
Authors
Keywords
Cost savings, Trough concentrations, Infliximab, Inflammatory bowel disease, Rheumatoid arthritis
Journal
JOURNAL OF GASTROENTEROLOGY
Volume 52, Issue 1, Pages 19-25
Publisher
Springer Nature
Online
2016-09-24
DOI
10.1007/s00535-016-1266-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Letter: infliximab de-escalation based on trough levels in patients with inflammatory bowel disease
- (2015) S. Paul et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Individualized Therapy Is a Long-Term Cost-Effective Method Compared to Dose Intensification in Crohn’s Disease Patients Failing Infliximab
- (2015) Casper Steenholdt et al. DIGESTIVE DISEASES AND SCIENCES
- Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
- (2015) Niels Vande Casteele et al. GASTROENTEROLOGY
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial
- (2014) Freddy Cornillie et al. GUT
- Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects
- (2013) C L M Krieckaert et al. ANNALS OF THE RHEUMATIC DISEASES
- Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
- (2013) Casper Steenholdt et al. GUT
- First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?
- (2013) Laurent Peyrin-Biroulet et al. Nature Reviews Gastroenterology & Hepatology
- Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
- (2012) Mirthe Emilie van der Valk et al. GUT
- Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients
- (2012) Filip Baert et al. Journal of Crohns & Colitis
- Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical Trials
- (2011) Adedigbo A. Fasanmade et al. CLINICAL THERAPEUTICS
- Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
- (2009) Javier P Gisbert et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
- (2009) Adedigbo A. Fasanmade et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started